NCT01398462

Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients

A Phase I Clinical Study of CWP232291 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome Having Failed Hypomethylating Treatment, and High-Risk Myelofibrosis

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 69 (actual)
• Sponsor: JW Pharmaceutical · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

CWP232291 blocks proliferation of cancer cells via activation of caspases. Active caspase have been shown to target beta-catenin, the hallmark of canonical Wnt signaling, for degradation through caspase-directed cleavage. CWP232291 targets beta-catenin for degradation and thereby inhibits the expression of cell cycle and anti-apoptotic genes such as cyclin D1 and survivin.

Conditions

• Acute Myeloid Leukemia
• Chronic Myelomonocytic Leukemia
• Myelodysplastic Syndrome
• Myelofibrosis

Interventions

Type	Name	Description
DRUG	CWP232291	IV Infusion

Timeline

• Start date: 2011-07-01
• Primary completion: 2015-12-01
• Completion: 2015-12-01
• First posted: 2011-07-20
• Last updated: 2016-03-08

Locations

5 sites across 2 countries: United States, South Korea